Policy / Regulatory

NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents

Fineline Cube
By
Fineline Cube
0 Min Read
Summarize with AI

The National Medical Products Administration released a notification extending the validation period of approvals for COVID-19 antigen detection reagents for another six months.

- Advertisement -

Current Approvals and Future Plans
The NMPA has approved 36 COVID-19 antigen detection reagents for marketing in China, with more to come.-Fineline Info & Tech

TAGGED:
Share This Article
Previous Article Science Standard Medical Testing Raises Pre-Series A Funding
Next Article Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

You May also Like

Policy / Regulatory

NMPA Releases 57th Batch of Reference Drugs for Generic Consistency Evaluation

Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies
DrugMedical Device

Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies

Policy / Regulatory

China’s NAFR Enhances Tax Benefits for Private Health Insurance Purchases

Policy / Regulatory

China Strengthens COVID-19 Prevention and Control in Rural Areas

Show More